NEW YORK, NY / ACCESSWIRE / December 21, 2017 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued an update on Nexeon MedSystems, Inc. (OTCQB: NXNN).

The report is available here: NXNN December 2017 Update Note.

Based in Dallas, TX, Nexeon MedSystems, Inc. (OTCQB, NXNN, “Nexeon”) is a medical device company focused on innovative bioelectronics, which combines telecommunications technology and biotechnology. The company’s novel solutions are designed to improve the quality of life for patients suffering from debilitating neurological diseases. Nexeon’s flagship product is the Nexeon Neurostimulation System (NNS), a neurostimulation and recording platform for deep brain stimulation (DBS). NNS is an adaptable bioelectronics solution, which includes a suite of advanced implantable medical devices, supporting devices, and patient management software. NNS is supported by an expansive portfolio of over 100 patents and patent applications and approximately $40mn of investment. The company has 13 patents granted in the US and 68 patents granted in Europe.

Highlights from the report include:

We are updating our coverage of Nexeon following recent results and the transformative acquisition of Nexeon MedSystems Belgium SPRL (“NMB”) and its subsidiary Medi-Line, a well-established manufacturer of medical devices with a 25-year operating history and annual revenues of $7.2mn in the fiscal year ended March 31, 2017.

Highlights of recent activities include:

Nexeon expanded its European presence and significant scale with the acquisition of NMB and its Medi-Line subsidiary.
Medi-Line brings the company an established base of business as a medical device manufacturer, serving 34 medical device customers in 16 countries including multi-year contracts with Fortune 500 companies including GE Health.
Medi-Line owns state-of-the-art facilities, which can be used to manufacture its DBS devices, and generated $7.2mn in revenue in its fiscal year ending March 31, 2017.
The impact of NMB and Medi-Line was apparent in 3Q17 results, even with only one month of contribution, as Nexeon reported revenues of $1.04mn, versus $0.19mn in 3Q16.
Nexeon continues to advance its flagship NNS neurostimulation and recording platform targeting the $910mn global market for deep brain stimulation (DBS).
Pending the re-certification of its CE Mark, Nexeon management announced that it planned to be in a position to launch its DBS product for Parkinson’s disease line in Europe by the end of 2018 with commercial revenues expected from the DBS product by 2Q19. In the United States, the company is beginning the pre-approval process with the FDA and is targeting a pivotal clinical study for NNS to commence in 1Q19.

Increasing Price Target to $2.85

We are increasing our target following the acquisition of NMB and Medi-Line, as Nexeon should benefit from the increased scale, revenues, and relationships from this transaction. The price target implies a multiple of 8.0x 2018E revenues of $10.0mn and 3.8x 2019E revenues of $21.2mn.

Please review important disclosures on our website at www.seethruequity.com.

About Nexeon Medsystems, Inc.

Nexeon Medsystems, Inc. (OTCQB: NXNN) is a global medical device company focused on providing innovative neurostimulation products that improve the quality of life of patients suffering from debilitating neurological diseases. Nexeon has developed and commercialized a neurostimulation system that can be utilized to treat a variety of neurological diseases (www.nexeonmed.com).

About SeeThruEquity

Since its founding in 2011, SeeThruEquity has been committed to its core mission: providing impactful, high quality research on underfollowed smallcap and microcap equities. SeeThruEquity has pioneered an innovative business model for equity research that is not paid for and is unbiased. SeeThruEquity is the host of acclaimed investor conferences that are the ultimate event for publicly traded companies with market capitalizations less than $1 billion.

SeeThruEquity is approved to contribute its research reports and estimates to Thomson One Analytics (First Call), the leading estimates platform on Wall Street, as well as Capital IQ and FactSet. SeeThruEquity maintains one of the industry’s most extensive databases of opt-in institutional and high net worth investors. The firm is headquartered in Midtown Manhattan in New York City.
For more information visit www.seethruequity.com.

Contact:

SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity

ReleaseID: 484772

NEW YORK, NY and LOS ANGELES, CA / ACCESSWIRE / December 21, 2017 / Dolphin Entertainment, Inc. (“Dolphin” or the “Company”) (NASDAQ: DLPN; NASDAQ: DLPNW), a publicly-traded independent producer of premium feature films and digital content, and parent company of 42West, one of the largest public relations and marketing services firms in the entertainment industry, today announced the pricing of 1,215,000 units at a price to the public of $4.125 per unit. Each unit issued in the offering consists of one share of common stock and one warrant to acquire one share of common stock at an exercise price of $4.74 per share. No units will be issued. The common stock and warrants are immediately separable from the units and will be issued separately. The common stock and warrants are expected to begin trading on The Nasdaq Capital Market (“Nasdaq”) on December 21, 2017, under the symbols “DLPN” and “DLPNW,” respectively. Dolphin expects to receive gross proceeds of $5,011,875, before deducting underwriting discounts and commissions and other estimated offering expenses.

Dolphin has granted the underwriters a 45-day option to purchase up to 182,250 additional shares of common stock, or warrants, or any combination thereof, at the public offering price to cover over-allotments, if any. The offering is expected to close on December 26, 2017, subject to customary closing conditions.

Maxim Group LLC and Ladenburg Thalmann & Co. Inc. are acting as joint book-running managers.

Dolphin intends to use the net proceeds from the offering for growth initiatives of its entertainment publicity business, including acquisitions of comparable businesses and groups with public relations expertise, the budgets for its content production business and general corporate purposes, including working capital.

The offering is being made only by means of a prospectus. When available, copies of the prospectus related to this offering may be obtained from Maxim Group LLC, 405 Lexington Ave, New York, NY 10174, Attn: Prospectus Department or by Tel: (800) 724-0761.

A registration statement relating to the securities was declared effective by the SEC on December 20, 2017. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Dolphin Entertainment, Inc.

Dolphin Entertainment is a leading independent entertainment marketing and premium content development company. Through our recent acquisition of 42West, we provide expert strategic marketing and publicity services to all of the major film studios, and many of the leading independent and digital content providers, as well as for hundreds of A-list celebrity talent, including actors, directors, producers and recording artists. 42West is a recognized global leader in PR services for the entertainment industry and, in December 2017, the New York Observer listed 42West as one of the top four most powerful PR firms of any kind in the United States. The strategic acquisition of 42West brings together premium marketing services with premium content production, creating significant opportunities to serve our respective constituents more strategically and to grow and diversify our business. Our content production business is a long established, leading independent producer, committed to distributing premium, best-in-class film and digital entertainment. We produce original feature films and digital programming primarily aimed at family and young adult markets.

Special Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including our expectations regarding our listing on Nasdaq, the closing of the proposed public offering, the gross proceeds from the offering, and the use of proceeds from the offering. These statements are based on our current expectations and are subject to certain risks and uncertainties that could cause actual results, performance or achievements to differ materially from those described in the forward-looking statements. These risks and uncertainties include our ability to satisfy the conditions to the closing of the offering; our ability to realize the anticipated benefits of the 42West acquisition; adverse events, trends and changes in the entertainment or entertainment marketing industries that could negatively impact 42West’s operations and ability to generate revenues; our ability to repay our debt when they become due; as well as other factors beyond our control and the risk factors and other cautionary statements described in our filings with the Securities and Exchange Commission (the “Commission”), including our Annual Report on Form 10-K filed with the Commission on April 17, 2017, as updated by subsequent Quarterly Reports on Form 10-Qs and other current report filings.

Any forward-looking statements included in this press release are made only as of the date of this release. We do not undertake any obligation to update or supplement any forward-looking statements to reflect subsequent events or circumstances. We cannot assure you that projected results or events will be achieved.

Contact:

James Carbonara
Hayden IR
(646)-755-7412
james@haydenir.com

SOURCE: Dolphin Entertainment, Inc.

ReleaseID: 484769

BOSTON, MA / ACCESSWIRE / December 21, 2017 / Zoom Telephonics, Inc. (“Zoom”) (OTCQB: ZMTP) has begun shipments of the Motorola MB7621, a 24×8 cable modem produced under exclusive license from Motorola Mobility LLC.

The MB7621 achieves very high Internet speeds by using a full-band capture digital tuner, 24 downstream cable channels, and 8 upstream cable channels. It supports very fast DOCSIS 3.0 cable Internet services including Comcast Xfinity Internet speeds up to 400 Mbps.

The MB7621 is certified by CableLabs, Comcast Xfinity, and Charter Spectrum. Additional cable service provider certifications are pending, and most other cable service providers require only CableLabs certification.

The Motorola MB7621 is available from Amazon now at $84.99.

“The Motorola MB7621 is an excellent cable modem with a great brand, and is well-positioned for success,” said Frank Manning, Zoom’s President and CEO. “Most customers will choose to use the MB7621 with a WiFi router such as the Motorola MR1700, Motorola MR1900, or a mesh router. Like all our cable modems, The MB7621 can be used instead of renting a service provider’s cable modem, saving $10 per month for Comcast and a range of savings for other service providers.”

About Zoom Telephonics

Zoom Telephonics, Inc. designs, produces, markets, and supports communication products under the Motorola and Zoom brands. The Company’s worldwide licensing agreement with Motorola includes cable modems and gateways, DSL modems and gateways, cellular modems and routers and sensors, range extenders, home powerline network products, and MoCA adapters. For more information about Zoom and its products, please visit www.zoomtel.com or www.motorolanetwork.com.

MOTOROLA and the Stylized M Logo are trademarks or registered trademarks of Motorola Trademark Holdings, LLC and are used under license.

ZOOM is a registered trademark of Zoom Telephonics, Inc.

Investor Relations Contact:

John Nesbett/Jennifer Belodeau
Institutional Marketing Services (IMS)
Phone: 203-972-9200
jnesbett@institutionalms.com

SOURCE: Zoom Telephonics, Inc.

ReleaseID: 484721

Effectively Covers the Incremental Cost of an Electric Drivetrain, Under Newly Approved $560 Million 2017-18 Budget, Allocated by California Clean Air Agency

CORONA, CA / ACCESSWIRE / December 21, 2017 / ADOMANI, Inc. (NASDAQ: ADOM) acknowledged today the increase in the California Air Resources Board (CARB), Hybrid and Zero-Emission Truck and Bus Voucher Incentive Project (HVIP) purchase incentive to $220,000 for the Blue Bird zero-emission electric, All American, Type-D school bus. The change in voucher amount was approved at a CARB Scoping Plan Board Meeting held December 14th during which their proposed Fiscal Year 2017-2018 Funding Plant for Clean Transportation Incentives was approved in full. The funding plan includes $180 million for clean truck and bus voucher incentives (HVIP), $140 million for advanced freight equipment demonstration and development, $140 million for light-duty vehicle incentives (CVRP), and $100 million for transportation equity projects.

“Once again, California has come through with funds that should accelerate the adoption of zero-emission electric transportation,” said Jim Reynolds, president and CEO of ADOMANI. “The increased incentive now essentially covers the incremental additional cost of the electric vehicle making the zero-emission choice more attainable for school districts as they update their fleets while protecting the health of their students, their drivers and the communities where they operate.”

The Hybrid and Zero-Emission Truck and Bus Voucher Incentive Project (HVIP) is a program created by CARB to help speed the early market introduction of clean, low-carbon hybrid and zero-emission trucks and buses. HVIP vouchers are intended to reduce the incremental costs of purchasing hybrid and zero-emission medium-duty and heavy-duty trucks and buses. The point-of-sale based voucher amount for the Blue Bird, “Powered By ADOMANI” All American, Type-D school bus has now increased from $95,000 to $220,000. If the bus operates in a Disadvantaged Community as defined by a CalEPA tool called CalEnviroScreen, the fleet operator can receive an incentive of $245,000 for their first 3 electric school buses and $235,000 per bus thereafter.

It’s anticipated that purchase orders will be accepted starting next month by Blue Bird dealers for the “Powered by ADOMANI” zero-emission electric school buses and that deliveries for the Type-D, All American will begin in mid-2018.

About the HVIP Program

The Hybrid and Zero-Emission Truck and Bus Voucher Incentive Project (HVIP) and Low NOx Engine Incentives was formed by the California Air Resources Board (CARB) as a result of the Air Quality Improvement Program (AQIP) following the passing of the California Alternative and Renewable Fuel, Vehicle Technology, Clean Air, and Carbon Reduction Act of 2007 (AB 118, Statutes of 2007, Chapter 750). AQIP offers funding for projects and initiatives focused on supporting the development and deployment of the advanced technologies needed to meet California’s longer-term, post-2020 air quality goals. The fuel efficiency and zero- to low-emission benefits of zero-emission, hybrid, and natural gas vehicle technologies provide a strong public health benefit by reducing harmful greenhouse gas (GHG) and criteria emissions.

HVIP responds to a key market challenge by making clean trucks and buses more affordable for fleets. By offering point-of-sale incentives for clean trucks and buses, HVIP provides a streamlined approach for providing helpful incentives to fleets without waiting to submit proposals or complicated paperwork. Fleets receive the voucher discount at the point of sale while HVIP-approved vendors and dealers process the required documentation.

To date, HVIP has deployed more than 2,700 medium- to heavy-duty vehicles, accelerating the growth of the nation’s early market of zero-emission and hybrid trucks and buses by 30 percent. HVIP has successfully increased the demand of these technologies which is proving to advance the industry, create jobs and economic benefits while accelerating the commercialization of these trucks and buses for all. With more than 1,000 fleets participating across California, HVIP is helping the state meet its clean air goals.

About ADOMANI

ADOMANI, Inc., is a provider of zero-emission electric and hybrid vehicles and replacement drivetrains that is focused on reducing the total cost of vehicle ownership. ADOMANI helps fleet operators unlock the benefits of green technology and address the challenges of traditional fuel price instability and local, state and federal environmental regulatory compliance. ADOMANI designs, manufactures, and installs advanced zero-emission electric and hybrid drivetrain systems for use in new school buses and medium to heavy-duty commercial fleet vehicles. For more information, visit www.ADOMANIelectric.com

Cautionary Statement Regarding Forward-Looking Statements

Statements made in this press release that relate to future plans, events, financial results, prospectus or performance are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. While they are based on the current expectations and beliefs of management, such forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors that could cause actual results to differ materially from the expectations expressed in this press release, including the risks and uncertainties disclosed in ADOMANI’s reports filed with the Securities and Exchange Commission, all of which are available online at www.sec.gov. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements containing the words “planned,” “expects,” “believes,” “strategy,” “opportunity,” “anticipates,” “outlook,” “designed,” and similar words. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, ADOMANI undertakes no obligation to update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events.

Contact Information

Investor Relations Contacts:
Michael K. Menerey, Chief Financial Officer
Telephone: (951) 407-9860 ext 205
Email: mike.m@ADOMANIelectric.com

Kevin Kanning, VP Investor Relations
Telephone: (650) 533-7629
Email: kevin.k@ADOMANIelectric.com

James Carbonara, Hayden IR
Telephone: (646) 755-7412
Email: james@haydenir.com

SOURCE: ADOMANI, Inc.

ReleaseID: 484726

CALGARY, AB / ACCESSWIRE / December 21, 2017 / Emerald Bay Energy Inc. (TSX-V: EBY, OTC PINK: EMBYF) (the “Company” or “Emerald Bay”) is pleased to announce that the Kuhn 4 well at Wooden Horse has been tied in and production operations have begun. Additional information will be forthcoming in the weeks ahead once initial production rates have stabilized.

About Emerald Bay

Emerald Bay Energy Inc. (EBY) is an energy company with oil producing properties in southwest Texas as well as non operated oil, natural gas, and electricity generation interests in Central Alberta, Canada. EBY is the operator of the Wooden Horse and Nash Creek Projects in Guadeloupe, Texas, where the Company currently now owns a 50.00% working interest in those projects. The Company also owns 75% of Production Resources Inc., a South Texas oil company.

To stay informed on Emerald Bay Energy, please join our Investor Group at https://www.8020connect.com/groups/emerald-bay-energy-inc for all upcoming news releases, articles, comments and questions.

For further information, please contact:

Emerald Bay President, Shelby D. Beattie, by telephone at (403) 262-6000

Email: info@ebyinc.com
www.ebyinc.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect,” “plan,” “intend,” “anticipates,” “projects,” “potential,” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Forward-looking statements are statements that are not historical facts.

Information inferred from the interpretation of drilling results may also be deemed to be forward-looking statements, as it constitutes a prediction of what might be found to be present when and if a well is actually developed. BOE’s may be misleading, particularly if used in isolation. A BOE conversion ratio of 6 Mcf: 1 Bbl is based on energy equivalency conversion method primarily applicable at the burner tip and does not represent a value equivalency at the wellhead. The reader is cautioned that assumptions used in the preparation of such information, which are considered reasonable by Emerald Bay at the time of preparation, may prove to be incorrect. Actual results achieved will vary from the information provided and the variations may be material. There is no representation by Emerald Bay that actual results achieved will be the same in whole or part as those indicated in the forward-looking statements. Forward-looking statements in this document include statements regarding the Company’s exploration, drilling and development plans, the Company’s expectations regarding the timing and success of such programs. In particular, forward-looking information in this news release includes, but is not limited to, statements with respect to: pipeline acquisitions and leasing; pipeline permits, pipeline construction, production estimates, drilling operations, completion operations, funding and development goals. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, level of activity, performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information. Factors that could cause or contribute to such differences include, but are not limited to, fluctuations in the prices of oil and gas, uncertainties inherent in estimating quantities of oil and gas reserves and projecting future rates of production and timing of development activities, competition, operating risks, acquisition risks, liquidity and capital requirements, the effects of governmental regulation, adverse changes in the market for the Company’s oil and gas production, dependence upon third-party vendors, and other risks detailed in the Company’s periodic report filings with the applicable securities regulators.

SOURCE: Emerald Bay Energy Inc.

ReleaseID: 484729

NEW YORK, NY / ACCESSWIRE / December 21, 2017 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued an update on Amarantus Bioscience Holdings, Inc. (OTC PINK: AMBS).

The report is available here: AMBS December 2017 Update Note.

Based in San Francisco, CA, Amarantus Bioscience Holdings, Inc. (OTC: AMBS, “Amarantus”) is a biotechnology company developing treatments and diagnostics for diseases in orphan neurologic, regenerative medicine and ophthalmic therapies, through three wholly-owned subsidiary companies. The company’s Elto Pharma subsidiary has development rights to eltoprazine, a Phase 2b-ready small molecule indicated for Parkinson’s disease levodopa-induced dyskinesia (PD-LID), Alzheimer’s aggression and adult ADHD. Amarantus has also acquired the rights to the Engineered Skin Substitute program (ESS), a Phase 3 ready regenerative medicine-based approach for treating severe burns with full-thickness autologous skin grown in tissue culture, which is being pursued by its subsidiary Cutanogen Corporation. Amarantus’ subsidiary MANF Therapeutics, Inc. is developing pre-clinical products as treatments for brain and ophthalmic disorders, which were discovered by CEO John Commissiong, PhD using its proprietary discovery engine PhenoGuard. AMBS also owns approximately 80 million shares of Avant Diagnostics, Inc. (OTC: AVDX) via the sale of its wholly-owned subsidiary Amarantus Diagnostics, Inc. that occurred in May 2016.

Highlights from the update note include:

We are updating our coverage of Amarantus following recent events, which included a plan for recapitalization plan and clinical update covering the company’s most advanced programs. Highlights of recent activities include:

Amarantus has disclosed a plan to move forward, restarting company activities in January 2018 with an aim to monetize its subsidiary companies through Reg A+ listings on Nasdaq CM or NYSE American, beginning with Elto Pharma, or other strategic transactions.
Amarantus has reached an agreement with holders of its senior secured convertible debt and convertible preferred securities to forbear the default provisions in these instruments and temporarily cease conversion of common shares.
As part of the agreement Amarantus will deliver to old debtholders its 80mn shares of Avant Diagnostics (AVDX) in a special purpose vehicle to be liquidated in an orderly fashion.
AMBS’ Elto Pharma subsidiary is preparing to restart its Phase 2b clinical trial for small molecule Eltoprazine for Parkinson’s disease levodopa-induced dyskinesia (PD-LID). Elto Pharma also has a Phase 3 ready program for Eltoprazine for treatment of agitation in dementia and in adult ADHD.
The company estimates the combined market opportunity for these two programs is in excess of $8 billion per year, based on the patient population and prices of comparable drugs on the market.

Updating Price Target to $0.65

We are updating the price target of AMBS following recent developments at the company. The target is based on the potential value from advancing candidates at Elto Pharma and Cutanogen, taking into consideration the liabilities at the AMBS level. We see the AMBS as a high risk, high potential reward company emerging from distressed status.

Please review important disclosures on our website at www.seethruequity.com.

About Amarantus Bioscience Holdings, Inc.

Amarantus Bioscience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases through its subsidiaries. AMBS’ wholly-owned subsidiary Elto Pharma, Inc. has development rights to eltoprazine, a Phase 2b-ready small molecule indicated for Parkinson’s disease levodopa-induced dyskinesia, Alzheimer’s aggression and adult ADHD. AMBS acquired the rights to the Engineered Skin Substitute program (ESS), a regenerative medicine-based approach for treating severe burns with full-thickness autologous skin grown in tissue culture that is being pursued by AMBS’ wholly-owned subsidiary Cutanogen Corporation. AMBS’ wholly-owned subsidiary MANF Therapeutics, Inc. owns key intellectual property rights and licenses from a number of prominent universities related to the development of the therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor (MANF). MANF Therapeutics, Inc. is developing MANF-based products as treatments for brain and ophthalmic disorders. MANF was discovered by the Company’s Chief Scientific Officer John Commissiong, PhD. Dr. Commissiong discovered MANF from AMBS’ proprietary discovery engine PhenoGuard. AMBS also owns approximately 80 million shares of Avant Diagnostics, Inc. via the sale of its wholly-owned subsidiary Amarantus Diagnostics, Inc. that occurred in May 2016. www.Amarantus.com.

About SeeThruEquity

Since its founding in 2011, SeeThruEquity has been committed to its core mission: providing impactful, high quality research on underfollowed smallcap and microcap equities. SeeThruEquity has pioneered an innovative business model for equity research that is not paid for and is unbiased. SeeThruEquity is the host of acclaimed investor conferences that are the ultimate event for publicly traded companies with market capitalizations less than $1 billion.

SeeThruEquity is approved to contribute its research reports and estimates to Thomson One Analytics (First Call), the leading estimates platform on Wall Street, as well as Capital IQ and FactSet. SeeThruEquity maintains one of the industry’s most extensive databases of opt-in institutional and high net worth investors. The firm is headquartered in Midtown Manhattan in New York City.
For more information visit www.seethruequity.com.

For more information visit www.seethruequity.com.

Contact:

SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity

ReleaseID: 484771